Medicines for end of life and rare conditions

Following an extensive review, the SMC has changed the way it evaluates end of life medicines and medicines to treat rare conditions. Pharmaceutical companies are able to request that SMC convenes a Patient and Clinician Engagement (PACE) meeting.

The PACE process gives patient groups and clinicians a stronger voice in SMC decision making. The documents below provide more detail and help explain what can be expected from the PACE meeting.

  • PACE Overview Document 261kb (PDF)

    Download

  • Patient Group Participation at a PACE Meeting 186kb (PDF)

    Download

Written statements

Pharmaceutical companies, clinical experts and patient groups are each invited to provide a written statement, which will be used as part of the PACE meeting.

Find out more about patient group participation in our PACE meetings

Watch Patient Group Partner Nic White talk about how patient groups are involved in our PACE meetings

Making submission

Public involvement

The views of patient groups and the public are key to what we do – and how we make our decisions.

Find out more
Observers at SMC Committee meeting

Register for a meeting

Register your interest in attending one of our SMC Committee meetings

Register